Article | December 17, 2021

Analysis: Pharma's Path Ahead For COVID-19 R&D

By Andrew Odame-Kwakye

iStock-1319551550-vaccine-covid

The therapeutic solutions and vaccines developed by the biopharma industry during the pandemic have allowed society to start imagining life after COVID-19. However, more tools and treatments are needed to control the virus. COVID-19 has become a leading cause of death worldwide, and continues to profoundly affect patients, families and societies and strain health care systems.

Three pressing issues stand out and require the collaborative efforts of the biopharma industry to slow the pandemic, reduce deaths and hospitalizations, and return life to something resembles normality: understanding long COVID, growing the arsenal of anti-infectives and tackling virus variants.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Informa Pharma Intelligence